



Drug Utilization Review Board Meeting

<u>Date</u>	<u>Time</u>	<u>Location</u>
July 20, 2023	10:00am – 3:00pm (CST)	MHD Building 615 Howerton Ct, Jefferson City, MO 65101 OR WebEx

[* Click HERE for Meeting Documents *](#)

<u>Board Members Present</u>	<u>MO HealthNet Staff Present</u>	<u>Contractors Present</u>
Charlene Hyde, PharmD Ginger Nicol, MD, CEDS Jennifer Passanise, FNP-BC Kimberly Eisenstein, MD Lisa Pierce, MD Rick Kegler, PharmD Sandra Bollinger, PharmD	Ambra Stotler-Bauda, Pharmacy Specialist Angela Wilson, Pharmacy Operations Manager Carmen Burton, Pharmacy Support Assistant Chelsea Hammond, Benefit Program Senior Specialist Connie Sutter, Fiscal Manager Danielle Dodd, Special Counsel Elizabeth Short, Program Development Specialist Elizabeth Sissom, RN, Clinical Review Nurse Jennifer Colozza, PharmD, Clinical Pharmacist Joshua Moore, PharmD, Director of Pharmacy Katie Affolder, UHSP Pharmacy Student Laurel Gibson, UMKC Pharmacy Student Lisa Smith, Pharmacy RFP Coordinator Mark Roaseau, R.Ph., Clinical Pharmacist Nikki Ashley, Pharmacy Program Specialist Olivia Rush, PharmD, Program Integrity Pharmacist Timothy Kling, MD, Acting Medical Director	Amanda Williams, PharmD, RPh, GWT Ashley Lytton, RN, BSN, Wipro Chelsea Pendleton, RN, BSN, Wipro Dimple Patel, PharmD, Conduent John Crowley, PharmD, BCPS, CPPS, Conduent Karen Powell, PharmD, MS, GWT LeAnna Kirsch, RN, Wipro Lokendra Upadhyay, PharmD, Conduent Lynn Morsches, PharmD, Conduent Mandy Nilges, RN, Wipro Megan Fast, PharmD, GWT Melissa Johnston, Conduent Sandy Kapur, PharmD, GWT Serena Barden, PharmD, BCPS, GWT
<u>Board Members Absent</u>		
Julie Ferguson, DO Stacy Mangum, PharmD		

Others Present:

Amanda Nowakowski

Angela Hailes

Ann Lyons

Bryan Moore

Clemice Hurst

Dan O'Donnell

Daphne Ni

Dave Poskey

Derrick Grass

Gene McCarty

Heather Fremi

Jason Enders

Jeff Knappen

Jen Tamburo

Jenny Carrell

Joe Payne

John Bullard

John Ford

Jomy Joseph

Jon Vlasnik

Kathrine Rivera

Keith Gulley

Kelly Ressel

Kheelan Gopal

Kurt Hendrickson

Mariola Vazquez

Matt Grewe

Melissa Basil

Melissa Glenski

Michelle Shirley

Phil Lohec

Rachelle Owens

Ricki Roberson

Rob Kilo

Rob Naismith

Scott Symes

Sean Jones

Shauna Williams

Stormy Cameron

Sunny Hirpara

Suzanne Morgan

Tom Seignious

<p>Welcome, Announcements and Introductions</p>	<p>Joshua Moore, MHD Pharmacy Director, introduced himself, Jennifer Colozza, MHD's new Clinical Pharmacist, Chelsea Hammond, MHD's Benefit Program Senior Specialist for the Pharmacy Administration Unit, Katie Affolder, UHSP Pharmacy Student, and Laurel Gibson, UMKC Pharmacy Student. Joshua called the meeting to order and facilitated the meeting on behalf of the MHD.</p>
<p>Minutes Review</p>	<p>Discussion: Minutes were reviewed from the April meeting.</p> <p>Decision: The Board voted to accept these approved minutes with no revisions.</p>
<p>Pharmacy Program and Budget Update</p>	<p>Elizabeth Short and Joshua Moore presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> - May 2023 Enrollees and Expenditures - July 2022 – May 2023 Expenditures by Service - FY20 – FY23 Pharmacy Expenditures vs Total Medicaid Expenditures - May 2023 Medicaid Expansion Participants, Expenditures, and Claim Count - FY19 to FY23 Mavyret Expenditures - FY23 Top 10 Drug Classes - CY23 Per User Per Month Drug Claim Reimbursement - FY20 – FY23 Rare Disease Expenditures Per Day - Additional information provided regarding: <ul style="list-style-type: none"> o Automatic Refill Regulation o CGM Utilization <ul style="list-style-type: none"> ▪ Board asked about provider reimbursement for insertion, education and readings of CGMs o Project Hep Cure o CMS – Diagnosis Code Requirement Comments o High Cost Medications Utilization Increases o Drug Shortages o Provider Manual and MHD Website Updates o The American Rescue Plan (ARP) Act of 2021 o Biosimilars – Recent approvals, Pipeline and AMP/CAP Discussions o Albuterol Utilization o Prior Authorization Helpdesk Hours

Old Business	
Old Business	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>These handouts were also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/dur/meeting.htm</p>
New Business	
New Drug Review	<p>Discussion:</p> <ul style="list-style-type: none"> - Olivia Rush reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> o A listing of products recommended for open access, clinical edit, step therapy, preferred drug list (PDL), or continue prior authorization was emailed to the Board for discussion and action. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the new drug recommendations with no revisions.</p>

Clinical and Fiscal Edit Review	
Clinical & Fiscal Edits With No Annual Changes	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o Ampyra Clinical Edit o Besremi Clinical Edit o C5 Complement Inhibitors Clinical Edit o CAR-T Cell Therapy Clinical Edit o Crysvita Clinical Edit o Duchenne Muscular Dystrophy (DMD) Clinical Edit o Gamifant Clinical Edit o Iron – Injectable Step Therapy Edit o Koselugo Clinical Edit o Luxturna Clinical Edit o Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Edit <ul style="list-style-type: none"> ▪ Jason Enders with Horizon Neurology provided public comment on Uplizna ▪ Rob Naismith with WashU provided public comment on Uplizna o Reblozyl Clinical Edit o TIMs, Small Molecule Janus Kinase (JAK) Inhibitors Clinical Edit o Tolvaptan Clinical Edit o Vyvgart Clinical Edit o Zometa Clinical Edit - No other discussion. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions and ask that Rare Disease review the NMOSD Clinical Edit for step-therapy appropriateness.</p>
Daybue Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

Enjaymo Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
Filspari Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
Givlaari Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
Joenja Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
Synagis Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Jennifer Passanise stated RSV was already prominent in SW MO in adults. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Tepezza Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Preferred Drug List Edit Review</p>	
<p>Preferred Drug Edits With No Annual Changes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o Alpha-Glucosidase Inhibitors o Amylin Analogs o Biguanides & Combinations o Cyropyrin-Associated Periodic Syndrome (CAPS) Agents o DPP-IV Inhibitors & Combinations o Erythropoiesis Stimulating Agents o GLP-1 Receptor Agonists & Combination Agents <ul style="list-style-type: none"> ▪ Derrick Grass with Novo Nordisk provided public comment on Ozempic ▪ Derrick Grass with Novo Nordisk provided public comment on Rybelsus ▪ Approval Criteria Proposed Additions: <ul style="list-style-type: none"> • For non-preferred agents: <ul style="list-style-type: none"> o Documented diagnosis of type 2 diabetes mellitus in the past year AND o Adequate therapeutic trial of metformin in the past year AND o Failure to achieve desired therapeutic outcomes with trial on 3 or more preferred agents for 3 months each o Insulin, Mixed o Insulin, Non-Analogs o Insulin, Rapid Acting o Luteinizing Hormone Releasing Hormone (LHRH)/Gonadotropin Releasing Hormone (GnRH) Agents, Oral o Meglitinides o Methotrexate Agents o Psoriasis Agents, Oral

	<ul style="list-style-type: none"> ○ Sulfonylureas, Second Generation ○ Thiazolidinediones & Combinations ○ TIMs, IL17 Antibody/IL17 Receptor Antagonists ○ TIMs, IL23 Inhibitors and IL23/IL12 Inhibitors <p>Decision: The Board voted to accept the recommended criteria with the proposed change.</p>
Atopic Dermatitis Agents, Immunomodulators	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
Bleeding Disorders Agents	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
Colony Stimulating Factors	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
Growth Hormone Agents, Somatropin	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

Growth Hormone Releasing Factors, Select Agents	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
Insulin, Long Acting	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Derrick Grass with Novo Nordisk provided public comment on Tresiba. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
Luteinizing Hormone Releasing Hormone (LHRH)/Gonadotropin Releasing Hormone (GnRH) Agents, Non-Oral	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
Multiple Sclerosis Agents, Injectable	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
Multiple Sclerosis Agents, Oral	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

Psoriasis Agents, Topical	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Mariola Vazquez with Dermavant provided public comment on Vtama. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
SGLT Inhibitors & Combination Agents	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
Thrombocytopenia Agents	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
TIMs, IL6 Receptor Inhibitors	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
TIMs, Janus Kinase (JAK) Inhibitors	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Heather Freml with AbbVie yielded public comment time back on Rinvoq. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>TIMs, Misc. Allergy & Asthma Related Monoclonal Antibodies</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Katherine Rivera-Spolijaric with WashU provided public comment on Dupixent. - Sunny Hirpara with AstraZeneca yielded public comment back on Fasenra. - Ann Lyons with Amgen provided public comment on Tezspire. - Approval Criteria Proposed Changes: <ul style="list-style-type: none"> o Requests for non-preferred agents: Participants must have documented failure to achieve desired therapeutic outcomes with a three month trial on at least X* preferred agent if indicated o *The number of preferred agents changes throughout per indication <p>Decision: The Board voted to accept the recommended criteria with the proposed change.</p>
<p>TIMs, Select Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>TIMs, TNF Inhibitors</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Ann Lyons with Amgen yielded public comment time back on Amjevita. - Ann Lyons with Amgen yielded public comment time back on Enbrel. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Urinary Tract Antispasmodics</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

Other Business	
Program Utilization Information – Conduent Update	<p>John Crowley with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Call Center Statistics - Missouri SmartPA POS Transparency Report - “Top 25” Drugs by Cost/Claims
RetroDUR Update	<p>Dimple Patel with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Recent RetroDUR Interventions: <ul style="list-style-type: none"> o Long-acting Injectable (LAI) Antipsychotic Use in Schizophrenia - Outcome Assessment: <ul style="list-style-type: none"> o Improving Short-acting Beta Agonist Utilization Safety Intervention o Hepatitis C Intervention o Concurrent Opioids and CNS Stimulants Intervention - Potential RetroDUR Interventions: <ul style="list-style-type: none"> o Gabapentin Dose - Other RetroDUR Interventions: <ul style="list-style-type: none"> o Concurrent Use of Opioids, Benzodiazepines, and Antipsychotics
Other	<p>MHD Webinars:</p> <ul style="list-style-type: none"> - Live webinars - Presented by Relias - Looking for hot topics to increase attendance <p>The Board provided topics and other outreach resources.</p>
Motion to Close	<p>Rick Kegler motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.</p>

NEXT MEETING: Wednesday, October 18, 2023
615 Howerton Court, Conference Room 202
Jefferson City, MO 65109 and WebEx

Roll Call for July 20, 2023				
	<u>Action Item</u>			
<u>Board Member</u>	April Meeting Minutes	All Recommendations: Block Vote for New Drug, CE, FE and PDL Edits	Closing	Adjournment
Charlene Heyde	Y	Y	A	A
Ginger Nicol	Y	Y	Y	Y
Jennifer Passanise	Y	Y	Y	Y
Julie Ferguson	A	A	A	A
Kim Eisenstein	MY	SY	Y	MY
Lisa Pierce	Y	Y	Y	Y
Rick Kegler	SY	MY; AB from Bleeding Disorder Agents PDL	MY	SY
Sandra Bollinger	Y	Y	SY	Y
Stacy Mangum	A	A	A	A

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain